Liquid Biopsy Market By Sample Type (Blood Sample, Urine Sample and Other Bio Fluids);By Application (Therapy Selection for Metastatic Breast Cancer (MBS), Therapy Selection for Other Metastatic Cancer and Molecular Health Monitoring);By Biomarker (Circulating Tumour Cells (CTC), Circulating Tumour DNA (ctDNA) and Exosomes);By Technology (Multi-gene-parallel Analysis (NGS) and Single Gene Analysis (PCR Microarrays));By End-user (Hospitals, Diagnostic Laboratories and Others (Research Institutes)) Global Forecasts 2017 To 2027

Date : Aug 2021

|

Report ID : 210

|

Category : Healthcare

|
Report Format:  PDF EXCEL PPT WORD

The Global Liquid Biopsy Market was valued at USD 2.4 Bn in 2020 and expected to reach USD 7.1 Bn by 2027, with a growing CAGR of 19.9% during the forecast period

The enhancement of Next-Generation Sequencing methods permitted the cancer researchers and scientists to detect tumor sub clones, rare somatic variants, and the free circulating DNA fragments. The development of new novel technologies and molecular tools intend to accelerate the market. Nevertheless, the increasing prevalence of cancerous fragments in the genetic compositions, surgical invasions and tumorous cases depending on the geography are some of the factors that promote the growth of the liquid biopsy market.

Liquid Biopsy Market

The increasing prevalence of various tumors and clinical trials are expected to propel the liquid biopsy market. The high adoption rate of liquid biopsy is one of the prominent driving factors of it. Many key players are on the verge of product launches and various acquisitions leading to promote the liquid biopsy market value of molecular detection assay. The awareness for healthy lifestyle, increase in awareness regarding various genetic disorders and breast cancers, drives the growth of liquid biopsy market.

Moreover, growing alertness regarding healthy and disease free, increase in organized retail marketing, rise in diseased population are considerably the major factors that boost the growth of liquid biopsy market.

Liquid Biopsy Market Segmentation:

By Sample Type

  • Blood Sample
  • Urine Sample
  • Other Bio Fluids (Tissue fluids and Saliva)

By Application

  • Therapy Selection for Metastatic Breast Cancer (MBS)
  • Therapy Selection for Other Metastatic Cancer
  • Molecular Health Monitoring Services

By Biomarker

  • Circulating Tumour Cells (CTC)
  • Circulating Tumour DNA (ctDNA)
  • Exosomes

By Technology

  • Multi-gene-parallel Analysis (NGS)
  • Single Gene Analysis (PCR Microarrays)

By End-user

  • Hospitals
  • Diagnostic Laboratories
  • Others (Research Institutes)

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Based on sample type, blood sample segment has gained tremendous market shares in 2020

Based on sample type, blood sample segment has gained tremendous liquid biopsy market shares in 2020 and is predicted to gain more during forecast period. This is due to the increase in increasing rate of diagnosis and detection propel the growth of industry in this segment.

Based on application, therapy selection for metastatic breast cancer (MBS) segment is expected to show high market shares in 2020 and expected to gain more during forecast period

Based on application, therapy selection for metastatic breast cancer (MBS) segment is expected to show high market shares in 2020 and expected to gain more during the forecast period. According to WHO- World health organization, in the year 2020 an estimate study was conducted by the organization which confirmed that 2.3 million women who were diagnosed with breast cancer. The other factors like rising demand for breast cancers, its diagnostics procedures, and the increasing continuous research in laboratories account for its growth in the liquid biopsy market.

According to CDC, an estimated of 1,806,590 new cancers are diagnosed in the United States and 606,520 number of people died from it in 2020. The mortality of cancer is 158.3 per 100,000 men and women per year.

Based on biomarker, the circulating tumor DNA (ctDNA) segment has gained tremendous market shares in 2020

Based on biomarker, the circulating tumor DNA (ctDNA) segment has gained tremendous market share in 2020 and expected to gain more during forecast period. The segment is expected to grow owing to the increase in research, the on-going genome project on going and the other genetic disorders combined with the rising prevalence of various tumors across the globe.

Based on technology, the multi-gene-parallel analysis (NGS) segment has gained tremendous market shares in 2020 and expected to gain more during forecast period

Based on technology, the multi-gene-parallel analysis (NGS) segment has gained tremendous market shares in 2020 and expected to grow furthermore. The usage and popularity of NGS and its accurate interpretation is expected to be the main reason behind the segment growth. The segment in the market is growing due to increasing need of easy, early, and accurate detection and diagnostic rate of genetic and congenital diseases. Late detection can be life threatening and so hence, techniques like NGS and others are preferred for clarity in the diagnosis.

Based on end-user, diagnostic laboratories segment has gained tremendous market shares in 2020 and expected to gain more during forecast period

Based on end-user, diagnostic laboratories segment has gained tremendous market shares in 2020 and expected to grow furthermore propel. The Increasing population and the prevalence of pharmacological treatments drive the rate of diagnosis of the Liquid Biopsy. The increasing clinical trials and ongoing research in the key industries are also expected to drive the segment in the liquid biopsy market during the forecast period. The research taking place for the drug production in concern with various cancers. The factors driving the liquid biopsy market include an increase in manufacturing units and research along with development by the key players and the product launches.

Based on region, North America has gained tremendous market shares in 2020 and expected to gain more during forecast period

Based on region, North America dominated the liquid biopsy market in 2020. This region has eventually promoted the use and demand for liquid biopsy and technologies to detect the cancer and genetic disorders. Further, increase in research and development centres, the high birth rate, creates an opportunity for the key players to develop for development of more high-quality products and enhance the growth of market in this region. Highly established infrastructures and machineries enhance the research and development.

Further, an increase in research and development centres and the high birth rate creates an opportunity for key players for development of high-quality products which enhances the growth of liquid biopsy market in this region.

Company Profiles and Competitive Intelligence

The key players operating in the Liquid Biopsy Market are:

  • Biocept, Inc.
  • MDxHealth
  • Myriad Genetics, Inc.
  • Bio-Rad Laboratories
  • QIAGEN
  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific Inc.
  • Genomic Health, Inc.
  • Illumina, Inc.
  • Vermillion, Inc.
  • Foundation Medicine, Inc.
  • OncoCyte Corporation
  • Veracyte, Inc, Inc.
  • Guardant Health, Inc.
  • NeoGenomics Laboratories, Inc.
  • Other Prominent Key Players
  • Personal Genome Diagnostics, Inc.
  • RainDance Technologies, Inc.
  • Trovagene Inc.
  • Adaptive Biotechnologies.
  • Cynvenio Biosystems, Inc.

The report also provides in-depth analysis of Liquid Biopsy Market dynamics such as drivers, restraints,  and opportunities.

Drivers

  • Rising Prevalence of Breast Cancer
  • Increasing Personalized Targeted Sequencing for Tumour
  • Increasing Demand for Early Detection and Prevention

Restraints

  • Ethical Limitations of Liquid Biopsy
  • Stringent Regulatory Operations

Opportunities

  • Increase In Demand of Targeted Therapies
  • Key Players and Rising Number of Mergers & Acquisitions Among Companies to Expand Their Portfolio in Liquid Biopsy Market

COVID-19 Impact on the Liquid Biopsy Market Analysis

The Covid-19 outbreak had experienced a positive impact on the liquid biopsy industry as it has highly affected the industries in terms of growth, economy, health, and mental wellbeing of every individual. Many molecular detections assay was used for the vaccine production for the COVID-19. This created an opportunity for the retailers and manufactures to increase their sale of liquid biopsy during the pandemic time. There was a disruption in manufacturing, supply chain facilities and consumer spending due to financial crisis.

According to World Health Organization and European Centre for Disease Prevention and Control, there are about 200 million confirmed cases of COVID-19 which have been reported globally. According to WHO-World Health Organization, the data submitted on 13 August 2021, there have been 205,338,159 confirmed cases of COVID-19, 4,333,094 deaths and 4,428,168,759 vaccine doses have been given. The region of Americas is affected mainly with about 79,622,691 confirmed cases.

The report also provides in-depth analysis of key trends in Liquid Biopsy Market

  • Increase in government initiatives, development in innovative techniques and demand for detection of cancers and other neurological disorders helps the liquid biopsy market sustain during pandemic.
  • Covid –19 has positively affected industry, as this pandemic induced Lockdown across the globe. This helps to decline the sales of liquid biopsy products in the market
  • Insufficient raw material and disruption in supply chain and manufacturing segment has badly affected the sales of market

The report also provides in-depth analysis of recent news developments and investments

  • On March 02, 2021, Agilent Technologies announced the acquisition of Resolution Bioscience for worth $695 million. This is focused on the acquisition to increase the hold in NGS testing and revenue.
  • On May 6, 2021, NeoGenomics acquired Inivata for worth $390M after the successful collaboration of lung cancer liquid biopsy for the genetic testing services.

The unique insights provided by Liquid Biopsy Market report also includes the following:

  • Opportunity mapping
  • Sector snapshot
  • Key players positioning matrix
  • Disease Prevalence for Cancer and diagnosis of Genetic Disorders by Region/Country
  • Market trends
  • Covid-19 impact analysis
  • Product comparison
  • Pre & Post COVID 19 impacts on Liquid Biopsy Market
  • Competitive landscape

Frequently Asked Questions (FAQs)

What is the size of the global liquid biopsy market?

The Global Liquid Biopsy Market was valued at USD 2.4 Bn in 2020 and is anticipated to reach USD 7.1 Bn by 2027

What is the estimated market growth rate of Liquid Biopsy industry?

The Liquid Biopsy Market is estimated to grow at a compound annual growth rate (CAGR) of 19.9% during 2021-2027

Which is the dominating region in the Liquid Biopsy Market?

In the base year 2020, North America accounted for major share in the liquid biopsy market

What is the major driver of Global Liquid Biopsy Market?

Increase in prevalence of various Cancers, genetic variation disorders drive the growth of global liquid biopsy market.

Who are the key players in the Liquid Biopsy industry?

Few key players include, but not limit up to: F. Hoffmann-La Roche Ltd., Biocept, Inc., MDxHealth, QIAGEN, Thermo Fisher Scientific Inc., Genomic Health, Inc., Illumina, Inc., Bio-Rad Laboratories, Vermillion, Inc., Foundation Medicine, Inc., OncoCyte Corporation, Veracyte, Inc, Inc., Guardant Health, Inc., Myriad Genetics, Inc., and NeoGenomics Laboratories, Inc..

Related Reports

Need specific market information ?

Ask for free product review call with the author

Share your specific research requirements for a customized report

Request for due diligence and consumer centric studies

Request for study updates, segment specific and country level reports

 

  1.  Introduction
    1. Product Outline
    2. What is Liquid Biopsy
    3. Analysis of Liquid Biopsy Market
    4. COVID -19 Impact
    5. Market Dynamics
      1. Drivers
      2. Restraints
      3. Opportunities
      4. Threats
  2. Liquid Biopsy Market by Sample Type
    1. Blood Sample
    2. Urine Sample
    3. Other Bio Fluids (Tissue fluids and Saliva)
  3. Liquid Biopsy Market by Application
    1. Therapy Selection for Metastatic Breast Cancer (MBS)
    2. Therapy Selection for Other Metastatic Cancer
    3. Molecular Health Monitoring Services
  4. Liquid Biopsy Market by Biomarker
    1. Circulating Tumor Cells (CTC)
    2. Circulating Tumor DNA (ctDNA)
    3. Exosomes
  5. Liquid Biopsy Market by Technology
    1. Multi-gene-parallel Analysis (NGS)
    2. Single Gene Analysis (PCR Microarrays)
  6. Liquid Biopsy Market by End-user
    1. Hospitals
    2. Diagnostic Laboratories
    3. Others (Research Institutes)
  7. Regional Analysis
    1. North America
      1. US
      2. Canada
    2. Europe
      1. Germany
      2. UK
      3. France 
      4. Spain
      5. Italy
      6. Rest Of Europe
    3. Asia Pacific
      1. China
      2. India
      3. Japan
      4. Australia
      5. Rest Of Asia Pacific
    4. Latin America
      1. Brazil
      2. Mexico
      3. Rest of Latin America
    5. Middle East and Africa
      1. GCC
      2. South Africa
      3. Rest of MEA
  8. Key Strategic Insights
  9. Market Analysis
    1. Opportunity Mapping
    2. Critical Success Factors
    3. Consumer Preferences
  10.  Key Market Trends / Recent Developments
  11. Competitive Scenario
    1. Mergers and Acquisitions
    2. Investments
    3. Joint Ventures
    4. New Product Launches
    5. Ranking of Key Players
  12. Key Global Players
    1. Biocept, Inc.
    2. MDxHealth
    3. Myriad Genetics, Inc.
    4. Bio-Rad Laboratories
    5. QIAGEN
    6. F. Hoffmann-La Roche Ltd.
    7. Thermo Fisher Scientific Inc.
    8. Genomic Health, Inc.
    9. Illumina, Inc.
    10. Vermillion, Inc.
    11. Foundation Medicine, Inc.
    12. OncoCyte Corporation
    13. Veracyte, Inc, Inc.
    14. Guardant Health, Inc.
    15. NeoGenomics Laboratories, Inc.
    16. Other Prominent Key Players

Choose License
Buy Now
Why Choose AllTheResearch?
  • Monthly market updates for 6 months
  • Online access of reports
  • Options to buy sections of report
  • Critically analysed research on “Quadrant Positioning” of your company.
  • Syndicated report along with a supplementary report with objective-based study
  • Get profiled in the reports. Expanding your visibility across our network of readers and viewers
  • We provide local market data in local language on request
  • A complementary co-branded white paper
  • Flat consulting fee based exclusive studies. Consult at the price of syndicate
  • Access to expert team for free transaction advisory service.


Quick Inquiry
Follow Us
Choose License
Buy Now